REducing Cardiometabolic Risk with SEmaglutide in Type 1 diabetes (RESET1)

People with type 1 diabetes are at increased risk of developing heart disease. Treatments are urgently needed to address risk factors including excess weight, insulin resistance, and high glucose levels. The RESET1 study is looking for adults to test whether semaglutide, a medication currently used to treat type 2 diabetes, can improve heart health in people with T1D. 

What’s involved?  

Participants will be given semaglutide or a placebo once a week for 26 weeks. The study will include blood and urine tests, body composition and liver scans. These will be done at the Garvan Institute of Medical Research in Darlinghurst, Sydney. 

What are the benefits of participating?  

By participating, you will learn about your metabolism and receive test results, including body composition and energy expenditure measurements. 

Want to know more?  

Email: RESET1@garvan.org.au or call Dr Ruth Frampton on 0491 731 769.